Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Obesity01:24

Obesity

1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

407
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
407
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Phytocompounds That Target White Adipose Tissue for Weight Loss: A Review Spanning From Ucp1 Induction in Rodents to Human Clinical Trials.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026
Same author

Pilot Study of Gallic Acid Cream as a Potential Treatment for Plaque Psoriasis.

Journal of medicinal food·2026
Same author

Sexual Dimorphism in the Relationship between Body Composition and Insulin Resistance in Older Adults.

Current developments in nutrition·2026
Same author

A Novel Method to Evaluate Insulin Sensitivity by Combining Continuous Glucose Monitoring and Urinary C-Peptide Excretion.

Diabetes, obesity & metabolism·2026
Same author

Improved Iron Status, but Not Protein Source, Is Related to Appetite, Satiety, and Mood in Women of Reproductive Age With Iron Deficiency: A Randomized Controlled Trial.

The Journal of nutrition·2026
Same author

Virtual Weight Management and Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Randomized Controlled Trial.

Obesity (Silver Spring, Md.)·2026
Same journal

Alcohol-Related Liver Disease: A Review.

JAMA·2026
Same journal

Online Prescribing of GLP-1 Receptor Agonists.

JAMA·2026
Same journal

Using AI Disagreement to Expose Gaps in Coverage Rules.

JAMA·2026
Same journal

Randomized Trials in Pregnancy.

JAMA·2026
Same journal

Randomized Trials in Pregnancy-Reply.

JAMA·2026
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
関連記事をすべて見る

関連する実験動画

Updated: May 5, 2026

Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.9K

構造化された商業プログラムと比較した自己援助による体重減少:ランダム化試験.

Stanley Heshka1, James W Anderson, Richard L Atkinson

  • 1New York Obesity Research Center, St Luke's/Roosevelt Hospital and Columbia University, New York, NY, USA. sh311@columbia.edu

JAMA
|April 10, 2003
PubMed
まとめ
この要約は機械生成です。

2年間の研究では,構造化された商業的な減量プログラムは,自助プログラムよりも大きな減量につながったことがわかりました. 両方のアプローチはいくつかの利点を示しましたが,商業的なプログラムはより有意で持続的な減量結果を提供しました.

さらに関連する動画

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

2.1K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

関連する実験動画

Last Updated: May 5, 2026

Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.9K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

2.1K
Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

科学分野:

  • 肥満に関する研究.
  • 行動医学は,行動医学である.
  • 公衆衛生は公衆衛生である.

背景:

  • 商業的な減量プログラムは,何百万人もの人々に役立つが,厳格な長期的な有効性データがない.
  • 商業的対自助的な体重管理の長期的な有効性を評価することは極めて重要です.

研究 の 目的:

  • 構造化された商用プログラムと対比して,自己援助の減量効果を比較する.
  • 2年以上にわたって維持された体重減少と健康上の利益を評価するために.

主な方法:

  • 423人の過体重/肥満の成人を対象とした2年間の多センターランダム化臨床試験です.
  • 参加者は,自助プログラムまたは商業的な減量プログラムに割り当てられました.
  • 主なアウトカムは体重変化であり,次要アウトカムにはボディマス指数と腰周量が含まれていました.

主要な成果:

  • 商業的な減量プログラムは,自助グループと比較して,1年および2年の両方の体重減少が著しく増加しました.
  • 商業グループの参加者は,腰周長とボディマス指数においてより大きな減少を示しました.
  • 体重減少とともに生物学的パラメータは改善したが,2年目にはグループ間の有意な差は最小限であった.

結論:

  • 構造化された商業的な減量プログラムは,2年間のセルフヘルプ介入と比較して,控えめだが優れた減量をもたらします.
  • この結果は,持続的な体重管理のための構造化された商業プログラムの有効性を強調しています.